third quarter of 2026
Filed Nov 4, 2026Neuronetics reported third-quarter total revenue growth of 12.5%, positive income from operations of $0.5 million, adjusted EBITDA of $1.9 million, and reaffirmed full-year revenue guidance.
Greenbrook revenue grew 20.1%, gross margin expanded to 52.2%, operating expenses declined 13%, and the company delivered positive income from operations and adjusted EBITDA. NeuroStar revenue growth was 1.8%, cash declined from December 31, 2025, and full-year operating and investing cash flow guidance remains negative.
Key metrics
shortened, hover for the filing’s print| Metric | Value | q/q | y/y |
|---|---|---|---|
| Total revenues, three months ended September 30, 2026 (in thousands)GAAP | $41.96M | – | 12.5% |
| Total cost of revenues, three months ended September 30, 2026 (in thousands)GAAP | $20.07M | – | – |
| Gross profit, three months ended September 30, 2026 (in thousands)GAAP | $21.89M | – | – |
| Gross margin, three months ended September 30, 2026GAAP | 52.2% | – | – |
| Sales and marketing expense, three months ended September 30, 2026 (in thousands)GAAP | $8.48M | – | – |
| General and administrative expense, three months ended September 30, 2026 (in thousands)GAAP | $11.68M | – | – |
| Research and development expense, three months ended September 30, 2026 (in thousands)GAAP | $1.19M | – | – |
| Total operating expenses, three months ended September 30, 2026 (in thousands)GAAP | $21.35M | – | decrease of $3.1 million, or 13% |
| Income (Loss) from operations, three months ended September 30, 2026 (in thousands)GAAP | $541K | – | increase of $7.9 million |
| Interest expense, three months ended September 30, 2026 (in thousands)GAAP | $2.14M | – | – |
| Other income, net, three months ended September 30, 2026 (in thousands)GAAP | −$47K | – | – |
| Net loss, three months ended September 30, 2026 (in thousands)GAAP | −$1.56M | – | – |
| Net loss attributable to Neuronetics stockholders, three months ended September 30, 2026 (in thousands)GAAP | −$1.69M | – | – |
| Net loss per share of common stock outstanding, basic and diluted attributable to Neuronetics stockholders, three months ended September 30, 2026GAAP | $(0.02) | – | – |
| Weighted average common shares outstanding, basic and diluted, three months ended September 30, 2026 (in thousands)GAAP | 77.00M | – | – |
| EBITDA, three months ended September 30, 2026 (in thousands)non-GAAP | $1.15M | – | – |
| Adjusted EBITDA, three months ended September 30, 2026 (in thousands)non-GAAP | $1.89M | – | increase of $6.6 million |
| Cash provided by operating and investing, third quarter of 2026other | $800K | – | – |
| Total revenues, nine months ended September 30, 2026 (in thousands)GAAP | $118.0M | – | – |
| Gross profit, nine months ended September 30, 2026 (in thousands)GAAP | $59.27M | – | – |
| Total operating expenses, nine months ended September 30, 2026 (in thousands)GAAP | $69.22M | – | – |
| Loss from operations, nine months ended September 30, 2026 (in thousands)GAAP | −$9.96M | – | – |
| Net loss attributable to Neuronetics stockholders, nine months ended September 30, 2026 (in thousands)GAAP | −$15.92M | – | – |
| Net loss per share of common stock outstanding, basic and diluted attributable to Neuronetics stockholders, nine months ended September 30, 2026GAAP | $(0.22) | – | – |
| Adjusted EBITDA, nine months ended September 30, 2026 (in thousands)non-GAAP | −$4.44M | – | – |
Segments
| Segment | Revenue | q/q | y/y |
|---|---|---|---|
| NeuroStar revenue, three months ended September 30, 2026The Company said it delivered a record third quarter within NeuroStar system sales and cited positive reception of expanded NeuroStar go-to-market options. | $15.77M | – | 1.8% |
| Greenbrook revenue, three months ended September 30, 2026The increase reflected continued growth of the Greenbrook business. The Company also cited revenue cycle management advances. | $26.19M | – | 20.1% |
Amounts quoted below without a unit are in thousands, as in the filing’s tables. Per-share figures are as printed.
full year 2026 outlook
- Revenue$160 million to $164 million
- Gross margin49% to 50%
- Operating expensesOperating expenses between $92.5 million and $95.5 million; operating expenses, less stock-based compensation, between $89 million and $92 million; estimated stock-based compensation of $3.5 million.
- NoteCash flow from operating and investing in the range of $(10.0) million to $(12.0) million.
What drove it
- Higher Greenbrook revenue was the primary driver of total revenue growth.
- Gross-margin expansion was primarily driven by the positive impact of the new go-to-market strategy and improved revenue cycle management within Greenbrook clinics.
- Lower sales and marketing expenses drove the reduction in operating expenses, partly offset by higher general and administrative expenses.
- The Company submitted a 510(k) application for an accelerated TMS protocol in August.
- The Company signed a distribution agreement with Wave Neuro and plans to seek FDA clearance to add NeuroStar as a TMS system compatible with Wave Neuro's PTSD indication.
- TrakStar integration with AdvancedMD is expected to become available to existing NeuroStar providers using AdvancedMD in the fourth quarter of 2026.
Concerns
- NeuroStar revenue increased 1.8% year-over-year, compared with Greenbrook revenue growth of 20.1%.
- Net loss attributable to Neuronetics stockholders was $(1,692) (in thousands) in the third quarter of 2026.
- Long-term debt, net, was $61,752 (in thousands) as of September 30, 2026.
- The full-year 2026 outlook calls for cash flow from operating and investing of $(10.0) million to $(12.0) million.
- Accelerated TMS and PTSD opportunities are dependent on FDA review or clearance.
What to watch
- Performance against full-year total revenue guidance of $160 million to $164 million.
- Progress toward the full-year gross margin outlook of 49% to 50%.
- Delivery of operating expenses between $92.5 million and $95.5 million and cash flow from operating and investing of $(10.0) million to $(12.0) million.
- Availability of the AdvancedMD integration in the fourth quarter of 2026.
- FDA review of the accelerated TMS 510(k) application and the planned FDA clearance effort for the Wave Neuro PTSD indication.
Balance sheet and cash flow
- Total cash as of September 30, 2026 was $27.9 million, consisting of cash and cash equivalents of $22.1 million and $5.8 million of restricted cash, compared to total cash of $34.1 million as of December 31, 2025.
- Cash and cash equivalents and restricted cash and cash equivalents at September 30, 2026 were $27,856 (in thousands), compared to $34,471 (in thousands) at September 30, 2025.
- Long-term debt, net, was $61,752 (in thousands) as of September 30, 2026, compared to $65,807 (in thousands) as of December 31, 2025.
- Net cash used in operating activities for the nine months ended September 30, 2026 was $(9,191) (in thousands), compared to $(21,282) (in thousands) for the nine months ended September 30, 2025.
- Net cash used in investing activities for the nine months ended September 30, 2026 was $(1,059) (in thousands), compared to $(585) (in thousands) for the nine months ended September 30, 2025.
- Net cash provided by financing activities for the nine months ended September 30, 2026 was $3,972 (in thousands), compared to $36,879 (in thousands) for the nine months ended September 30, 2025.
- Proceeds from issuance of common stock under the ATM Program were $8,577 (in thousands) for the nine months ended September 30, 2026.
Analysis
Neuronetics delivered $41,962 thousand of total revenue in the third quarter of 2026, compared with $37,297 thousand in the third quarter of 2025. Greenbrook produced $26,192 thousand of revenue and grew 20.1%, while NeuroStar revenue was $15,770 thousand and grew 1.8%. The release identifies continued Greenbrook business growth as the principal revenue driver and describes record third-quarter performance in Greenbrook and NeuroStar system sales.
The operating model improved materially. Gross margin increased to 52.2% from 45.9%, which the Company attributed to its new go-to-market strategy and improved Greenbrook revenue cycle management. Total operating expenses declined to $21,349 thousand from $24,429 thousand, led by lower sales and marketing expense. Income from operations was $541 thousand, compared with a loss from operations of $(7,321) thousand, and adjusted EBITDA was $1,887 thousand, compared with $(4,670) thousand.
Below operating income, interest expense was $2,144 thousand and net loss attributable to Neuronetics stockholders was $(1,692) thousand, or $(0.02) per basic and diluted share. For the nine months ended September 30, 2026, net cash used in operating activities was $(9,191) thousand and net cash used in investing activities was $(1,059) thousand. Total cash at September 30, 2026 was $27.9 million, while long-term debt, net, was $61,752 thousand.
The full-year revenue outlook remains $160 million to $164 million. The gross-margin outlook is 49% to 50%, compared with prior guidance of 48% to 50%, while operating expense and operating-and-investing cash-flow outlooks were reduced from the prior ranges stated in the release. Operationally, the Company has an accelerated TMS 510(k) under review, plans to seek clearance for NeuroStar compatibility with Wave Neuro's PTSD indication, and expects its AdvancedMD integration to become available to existing NeuroStar providers using AdvancedMD in the fourth quarter of 2026.
Management, verbatim
This quarter showed our strategy taking hold across our business. We delivered a record third quarter within Greenbrook as well as NeuroStar system sales. This reflects both our revenue cycle management advances as well as the positive reception of our expanded NeuroStar go-to-market options. We also continued to demonstrate our prioritization on profitability and cashflow generation.
Dan Reuvers, President and Chief Executive Officer of Neuronetics
Not in the filing
stated, not guessed- Prior-quarter comparisons for reported third-quarter operating metrics.
- Quarterly operating cash flow and quarterly investing cash flow presented separately.
- Free cash flow.
- Dividends and share repurchases.
- Income-tax rate.
- Full-year adjusted EBITDA guidance.
- The previous outlook covered the full year 2026 only, so there is nothing to compare for this quarter.
Written by an AI language model from the company’s SEC earnings filing (Form 8-K Item 2.02, or Form 6-K for a foreign private issuer). Every figure is checked against the filing text, and a metric the filing does not print, or whose value, prior period and change do not add up, is dropped from the metrics. Guided figures in the outlook comparison come from the company’s previous release. The model can still misread a table, in the metrics or in the text, so check a number in the filing before you rely on it. Consensus estimates, price targets and share-price reactions are not shown because they are not in the filing. AI-generated research, not investment advice.